{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"73.8","upperLimit":"89.3","value":"82.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"}],"units":"Participants"}],"description":"A DCR was defined as the proportion of participants with objective evidence of CR, PR, or SD, except that there was no requirement for a confirmation of an SD response, if it is maintained for at least 6 weeks post treatment initiation. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes might had reduction in short axis to \\<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the Baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taken as a reference the smallest sum diameters while on study. DCR was based on IRC.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with iCCA with tumors harboring FGFR2 gene rearrangements received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG000","title":"Phase 2"}],"paramType":"NUMBER","populationDescription":"Efficacy population included all treated iCCA participants with confirmed FGFR2 gene fusions or other FGFR2 rearrangements who had received at least 1 dose of TAS-120.","reportingStatus":"POSTED","timeFrame":"Up to approximately 37.5 months (through cut-off date 29-May-2021)","title":"Phase 2: Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}